MYC multimers shield stalled replication forks from RNA polymerase.
Daniel SolvieApoorva BaluapuriLeonie UhlDaniel FleischhauerTheresa EndresDimitrios PapadopoulosAmel AzibaAbdallah GaballaIvan MikicicEkaterina IsaakovaCeleste GiansantiJennifer JansenMarvin JungblutTeresa KleinChristina Schülein-VölkHans Michael MaricSören DooseMarkus SauerPetra BeliAndreas RosenwaldMatthias DobbelsteinElmar WolfMartin EilersPublished in: Nature (2022)
Oncoproteins of the MYC family drive the development of numerous human tumours 1 . In unperturbed cells, MYC proteins bind to nearly all active promoters and control transcription by RNA polymerase II 2,3 . MYC proteins can also coordinate transcription with DNA replication 4,5 and promote the repair of transcription-associated DNA damage 6 , but how they exert these mechanistically diverse functions is unknown. Here we show that MYC dissociates from many of its binding sites in active promoters and forms multimeric, often sphere-like structures in response to perturbation of transcription elongation, mRNA splicing or inhibition of the proteasome. Multimerization is accompanied by a global change in the MYC interactome towards proteins involved in transcription termination and RNA processing. MYC multimers accumulate on chromatin immediately adjacent to stalled replication forks and surround FANCD2, ATR and BRCA1 proteins, which are located at stalled forks 7,8 . MYC multimerization is triggered in a HUWE1 6 and ubiquitylation-dependent manner. At active promoters, MYC multimers block antisense transcription and stabilize FANCD2 association with chromatin. This limits DNA double strand break formation during S-phase, suggesting that the multimerization of MYC enables tumour cells to proliferate under stressful conditions.